$120.17
0.86% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US64125C1099
Symbol
NBIX
Sector
Industry

Neurocrine Biosciences, Inc. Target price 2024 - Analyst rating & recommendation

Neurocrine Biosciences, Inc. Classifications & Recommendation:

Buy
86%
Hold
14%

Neurocrine Biosciences, Inc. Price Target

Target Price $169.52
Price $120.17
Potential
Number of Estimates 23
23 Analysts have issued a price target Neurocrine Biosciences, Inc. 2025 . The average Neurocrine Biosciences, Inc. target price is $169.52. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 28 analysts: 24 Analysts recommend Neurocrine Biosciences, Inc. to buy, 4 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Neurocrine Biosciences, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Neurocrine Biosciences, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Billion $ 1.89 2.33
26.76% 23.39%
EBITDA Margin 22.05% 31.00%
23.26% 40.59%
Net Margin 13.21% 21.33%
24.91% 61.51%

24 Analysts have issued a sales forecast Neurocrine Biosciences, Inc. 2024 . The average Neurocrine Biosciences, Inc. sales estimate is

$2.3b
Unlock
. This is
9.86% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$2.4b 12.37%
Unlock
, the lowest is
$2.2b 4.50%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $1.9b 26.76%
2024
$2.3b 23.39%
Unlock
2025
$2.7b 16.48%
Unlock
2026
$3.2b 17.17%
Unlock
2027
$3.6b 12.20%
Unlock
2028
$4.0b 12.80%
Unlock

8 Analysts have issued an Neurocrine Biosciences, Inc. EBITDA forecast 2024. The average Neurocrine Biosciences, Inc. EBITDA estimate is

$722m
Unlock
. This is
26.77% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$934m 64.06%
Unlock
, the lowest is
$617m 8.33%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $416m 56.25%
2024
$722m 73.47%
Unlock
2025
$936m 29.67%
Unlock
2026
$1.3b 37.85%
Unlock
2027
$1.6b 24.81%
Unlock
2028
$1.9b 17.78%
Unlock

EBITDA Margin

2023 22.05% 23.26%
2024
31.00% 40.59%
Unlock
2025
34.51% 11.32%
Unlock
2026
40.60% 17.65%
Unlock
2027
45.16% 11.23%
Unlock
2028
47.16% 4.43%
Unlock

23 Neurocrine Biosciences, Inc. Analysts have issued a net profit forecast 2024. The average Neurocrine Biosciences, Inc. net profit estimate is

$497m
Unlock
. This is
48.73% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$696m 108.46%
Unlock
, the lowest is
$350m 4.93%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $249m 58.33%
2024
$497m 99.31%
Unlock
2025
$694m 39.67%
Unlock
2026
$933m 34.48%
Unlock
2027
$1.1b 19.62%
Unlock
2028
$1.4b 21.71%
Unlock

Net Margin

2023 13.21% 24.91%
2024
21.33% 61.51%
Unlock
2025
25.58% 19.92%
Unlock
2026
29.36% 14.78%
Unlock
2027
31.30% 6.61%
Unlock
2028
33.77% 7.89%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ 2.47 4.92
58.33% 99.19%
P/E 24.41
EV/Sales 4.89

23 Analysts have issued a Neurocrine Biosciences, Inc. forecast for earnings per share. The average Neurocrine Biosciences, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$4.92
Unlock
. This is
48.64% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$6.90 108.46%
Unlock
, the lowest is
$3.47 4.83%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $2.47 58.33%
2024
$4.92 99.19%
Unlock
2025
$6.88 39.84%
Unlock
2026
$9.25 34.45%
Unlock
2027
$11.06 19.57%
Unlock
2028
$13.46 21.70%
Unlock

P/E ratio

Current 36.30 40.48%
2024
24.41 32.75%
Unlock
2025
17.48 28.39%
Unlock
2026
13.00 25.63%
Unlock
2027
10.86 16.46%
Unlock
2028
8.93 17.77%
Unlock

Based on analysts' sales estimates for 2024, the Neurocrine Biosciences, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.37 11.09%
2024
4.89 8.93%
Unlock
2025
4.20 14.15%
Unlock
2026
3.58 14.66%
Unlock
2027
3.19 10.87%
Unlock
2028
2.83 11.35%
Unlock

P/S ratio

Current 5.73 11.34%
2024
5.21 8.97%
Unlock
2025
4.47 14.15%
Unlock
2026
3.82 14.65%
Unlock
2027
3.40 10.87%
Unlock
2028
3.02 11.35%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today